Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Ballow

Showing results (11-20 of 94) with videos related to

Pageof 10
Sort By:
The Journal of Allergy and Clinical Immunology|June 30, 2012
Vaccines in the assessment of patients for immune deficiencyMark Ballow
The Journal of Allergy and Clinical Immunology|October 8, 2005
-ximab this and -zumab that! Has the magic bullet arrived in the new millennium of medicine and science?Mark Ballow
Journal of Clinical Immunology|April 25, 2012
SummaryMark Ballow
The Journal of Allergy and Clinical Immunology|April 10, 2002
Primary immunodeficiency disorders: antibody deficiencyMark Ballow
Immunologic Research|October 6, 2007
Safety of IGIV therapy and infusion-related adverse eventsMark Ballow
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 26, 2013
Optimizing immunoglobulin treatment for patients with primary immunodeficiency disease to prevent pneumonia and infection incidence: review of the current dataMark Ballow
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 26, 2013
Managing comorbid complications in patients with common variable immunodeficiencyMark Ballow
The Journal of Allergy and Clinical Immunology|December 28, 2010
The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disordersMark Ballow
The Journal of Allergy and Clinical Immunology|December 13, 2006
Biologic immune modifiers: Trials and tribulations--are we there yet?Mark Ballow
Journal of Clinical Immunology|June 26, 2012
Dosing and therapy utilization: a discussion of updates on PI treatment guidelinesMark Ballow
Pageof 10

Showing results (11-20 of 94) with videos related to

Sort By:
Pageof 10
The Journal of Allergy and Clinical Immunology|June 30, 2012
Vaccines in the assessment of patients for immune deficiencyMark Ballow
The Journal of Allergy and Clinical Immunology|October 8, 2005
-ximab this and -zumab that! Has the magic bullet arrived in the new millennium of medicine and science?Mark Ballow
Journal of Clinical Immunology|April 25, 2012
SummaryMark Ballow
The Journal of Allergy and Clinical Immunology|April 10, 2002
Primary immunodeficiency disorders: antibody deficiencyMark Ballow
Immunologic Research|October 6, 2007
Safety of IGIV therapy and infusion-related adverse eventsMark Ballow
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 26, 2013
Optimizing immunoglobulin treatment for patients with primary immunodeficiency disease to prevent pneumonia and infection incidence: review of the current dataMark Ballow
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 26, 2013
Managing comorbid complications in patients with common variable immunodeficiencyMark Ballow
The Journal of Allergy and Clinical Immunology|December 28, 2010
The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disordersMark Ballow
The Journal of Allergy and Clinical Immunology|December 13, 2006
Biologic immune modifiers: Trials and tribulations--are we there yet?Mark Ballow
Journal of Clinical Immunology|June 26, 2012
Dosing and therapy utilization: a discussion of updates on PI treatment guidelinesMark Ballow
Pageof 10